Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

News

EVELO BIOSCIENCES APPOINTS JULIE CARRETERO AS CHIEF PEOPLE OFFICER
Cambridge, MA - September 14, 2020

EVELO BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBER
Cambridge, MA - September 8, 2020

EVELO BIOSCIENCES REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - July 30, 2020

EVELO BIOSCIENCES TO PRESENT CLINICAL DATA FROM PHASE 1/2 TRIAL OF EDP1503 AT THE ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER VIRTUAL MEETING
Cambridge, MA - July 1, 2020

EVELO BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Cambridge, MA - June 24, 2020

EVELO BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Cambridge, MA - June 24, 2020

EVELO BIOSCIENCES ANNOUNCES EDP1815 TO ADVANCE INTO PHASE 2/3 TACTIC-E COVID-19 TRIAL
Cambridge, MA - June 22, 2020

EVELO BIOSCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - May 11, 2020

EVELO BIOSCIENCES, RUTGERS UNIVERSITY, AND ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL ANNOUNCE SUBMISSION OF IND FOR A PHASE 2 STUDY OF EDP1815 IN COVID-19 PATIENTS
Cambridge, MA - May 7, 2020

EVELO BIOSCIENCES TO REPORT FIRST QUARTER 2020 FINANCIAL RESULTS ON MONDAY, MAY 11, 2020
Cambridge, MA - May 4, 2020

EVELO BIOSCIENCES APPOINTS NEIL GRAHAM, M.D., M.B.B.S., M.P.H., AS CHIEF DEVELOPMENT OFFICER
Cambridge, MA - April 15, 2020

EVELO BIOSCIENCES ANNOUNCES BIOMARKER DATA SHOWING EDP1815 IS AN ORALLY DELIVERED DUAL CYTOKINE INHIBITOR FOR INFLAMMATORY DISEASES
Cambridge, MA - March 2, 2020

EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - February 13, 2020

EVELO BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 13, 2020
Cambridge, MA - February 6, 2020

EVELO PROVIDES UPDATE ON RECENT POSITIVE EDP1815 REGULATORY INTERACTIONS ON PHASE 2 TRIAL DESIGN RESULTING IN SHORTER DEVELOPMENT TIMELINE TO REGISTRATION
Cambridge, MA - January 10, 2020

EVELO BIOSCIENCES APPOINTS JUAN ANDRES TO BOARD OF DIRECTORS
Cambridge, MA - December 5, 2019

EVELO BIOSCIENCES TO PRESENT PRECLINICAL DATA FROM ITS EDP1503 ONCOLOGY PROGRAM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC) ANNUAL MEETING
Cambridge, MA - November 8, 2019

EVELO BIOSCIENCES REPORTS FURTHER POSITIVE EDP1815 INTERIM CLINICAL DATA IN PATIENTS WITH PSORIASIS AT HIGH DOSE IN PHASE 1B TRIAL
Cambridge, MA - November 5, 2019

EVELO BIOSCIENCES ANNOUNCES FURTHER POSITIVE INTERIM PHASE 1B CLINICAL DATA IN PSORIASIS AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS
Cambridge, MA - November 5, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON TUESDAY, NOVEMBER 5TH
November 4, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON TUESDAY, NOVEMBER 5TH
Cambridge, MA - October 29, 2019

EVELO BIOSCIENCES TO HOST KEY OPINION LEADER SYMPOSIUM ON UNMET NEED IN MILD TO MODERATE PSORIASIS AND POTENTIAL FOR EDP1815
Cambridge, MA - October 2, 2019

EVELO BIOSCIENCES TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - October 2, 2019

EVELO BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DAVID EPSTEIN AS CHAIRMAN OF ITS BOARD OF DIRECTORS
Cambridge, MA - September 17, 2019

EVELO BIOSCIENCES TO PRESENT AT THE MORGAN STANLEY 17TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - September 3, 2019

EVELO BIOSCIENCES REPORTS POSITIVE EDP1815 INTERIM CLINICAL DATA IN PSORIASIS PATIENTS AT LOW DOSE IN ONGOING PHASE 1B TRIAL
Cambridge, MA - August 6, 2019

EVELO BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 1B CLINICAL DATA AND PROVIDES SECOND QUARTER 2019 FINANCIAL RESULTS
Cambridge, MA - August 6, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON TUESDAY, AUGUST 6TH
Cambridge, MA - July 30, 2019

EVELO BIOSCIENCES SECURES $45 MILLION DEBT FINANCING FROM K2 HEALTHVENTURES
Cambridge, MA - July 25, 2019

EVELO BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN JUNE
Cambridge, MA - May 30, 2019

EVELO BIOSCIENCES TO PRESENT AT 2019 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - May 15, 2019

EVELO BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - May 2, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON THURSDAY, MAY 2, 2019
Cambridge, Mass. - April 25, 2019

EVELO BIOSCIENCES TO PRESENT AT 18TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Cambridge, Mass. - April 3, 2019

EVELO BIOSCIENCES TO PRESENT AT 39TH ANNUAL COWEN & CO. HEALTH CARE CONFERENCE
Cambridge, Mass. - March 4, 2019

EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, Mass. - February 14, 2019

EVELO BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 14, 2019
Cambridge, Mass. - February 7, 2019

EVELO BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN INVESTIGATOR-SPONSORED PHASE 2A CLINICAL TRIAL OF EDP1503 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
Cambridge, Mass. - January 28, 2019

EVELO BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2 CLINICAL TRIAL OF EDP1503 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN MULTIPLE ONCOLOGY INDICATIONS
Cambridge, Mass. - January 4, 2019

EVELO ENTERS INTO CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK
Cambridge, Mass. - November 27, 2018

EVELO BIOSCIENCES ANNOUNCES FIRST DOSING IN PHASE 1B CLINICAL TRIAL OF EDP1815 IN PSORIASIS AND ATOPIC DERMATITIS
Cambridge, Mass. - November 26, 2018

EVELO BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - November 1, 2018

EVELO BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - August 2, 2018

EVELO BIOSCIENCES ADDED TO RUSSELL 3000®, 2000® AND MICROCAP® INDEXES
Cambridge, Mass. - June 25, 2018

EVELO BIOSCIENCES TO PRESENT AT THE JMP SECURITIES 2018 LIFE SCIENCES CONFERENCE
Cambridge, Mass. - June 14, 2018

EVELO BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - May 31, 2018

EVELO BIOSCIENCES ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
Cambridge, Mass. - May 8, 2018

EVELO BIOSCIENCES EXPANDS EXECUTIVE LEADERSHIP TEAM
Cambridge, Mass. - February 8, 2018

EVELO BIOSCIENCES ANNOUNCES ISSUANCE OF U.S. PATENT SUPPORTING MONOCLONAL MICROBIAL ONCOLOGY TRIALS
Cambridge, Mass. - January 9, 2018

EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017

EVELO BIOSCIENCES ANNOUNCES $50 MILLION SERIES B FINANCING AND EXPANSION OF BOARD AND LEADERSHIP TEAM
Cambridge, Mass. - July 11, 2017

EVELO BIOSCIENCES TO PRESENT AT BIOCENTURY NEWSMAKERS CONFERENCE
Cambridge, Mass. - September 6, 2016

EVELO BIOSCIENCES AND MAYO CLINIC ESTABLISH RESEARCH COLLABORATION FOR IMMUNO-MICROBIOME CANCER THERAPIES
Cambridge, Mass. - August 2, 2016

EVELO BIOSCIENCES AND EPIVA BIOSCIENCES MERGE TO CREATE THE LEADING IMMUNO-MICROBIOME COMPANY
Cambridge, Mass. - July 12, 2016

EVELO BIOSCIENCES PARTICIPATES IN WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY'S NATIONAL MICROBIOME INITIATIVE EVENT
Cambridge, Mass. - May 13, 2016

EVELO BIOSCIENCES ANNOUNCES PARTICIPATION AT GUGGENHEIM MICROBIOME DAY
Cambridge, Mass. - April 14, 2016

UCHICAGO AND EVELO BIOSCIENCES SIGN LICENSING DEAL FOR MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - April 7, 2016

EVELO BIOSCIENCES ESTABLISHES SCIENTIFIC ADVISORY BOARD
Cambridge, Mass. - March 29, 2016

EVELO THERAPEUTICS ESTABLISHES CORE EXECUTIVE TEAM
Cambridge, Mass. - January 11, 2016

EVELO THERAPEUTICS EXPANDS TO NEW HEADQUARTERS IN CAMBRIDGE
Cambridge, Mass. - December 18, 2015

UCHICAGO AND EVELO THERAPEUTICS PARTNER TO ADVANCE MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - November 9, 2015

FLAGSHIP VENTURES LAUNCHES EVELO THERAPEUTICS TO DEVELOP MICROBIOME THERAPIES FOR CANCER
Cambridge, Mass. - November 4, 2015